全国筛查项目中对腺瘤或结直肠癌常规进行林奇综合征分子分析
本研究在荷兰全国结直肠癌筛查项目中对1101例粪便免疫化学检测阳性后转诊至伊拉斯姆斯医学中心的参与者进行前瞻性研究,对晚期腺瘤、≥4个非晚期腺瘤或结直肠癌组织行错配修复蛋白免疫组化检测以筛查林奇综合征。结果显示,56例结直肠癌中7例(13%)存在错配修复蛋白缺失,其中5例MLH1启动子高甲基化;400例腺瘤中仅1例存在错配修复蛋白缺失,该腺瘤携带2个体细胞MSH6突变,未发现林奇综合征个体。
要点
- 在1101例筛查阳性参与者中,456例(41%)有结直肠癌和/或符合免疫组化分析条件的腺瘤。
- 56例结直肠癌中7例(13%)存在错配修复蛋白缺失,其中5例MLH1启动子高甲基化,2例无MLH1启动子高甲基化者经肿瘤DNA分析为散发性肿瘤。
- 400例腺瘤中仅1例存在错配修复蛋白缺失,该腺瘤携带2个体细胞MSH6突变,未发现林奇综合征个体。
核心结论
- 在荷兰55至75岁人群的结直肠癌筛查项目中,对晚期及多发腺瘤患者结肠组织常规行免疫组化筛查林奇综合征未发现林奇综合征个体。
研究设计与样本
- 前瞻性研究,纳入2013年12月至2016年12月粪便免疫化学检测阳性后转诊至荷兰伊拉斯姆斯医学中心的参与者1101例(55%男性;中位年龄66岁;四分位距61-70岁),对晚期腺瘤、≥4个非晚期腺瘤或结直肠癌组织行错配修复蛋白(MLH1、MSH2、MSH6或PMS2)免疫组化检测。
主要发现
- 结肠镜检查发现456例(41%)有结直肠癌和/或符合免疫组化分析条件的腺瘤(65%男性;平均年龄67岁;四分位距63-71岁)。
- 56例结直肠癌中7例(13%)存在错配修复蛋白缺失,其中5例MLH1启动子高甲基化;肿瘤DNA分析显示2例无MLH1启动子高甲基化患者为散发性肿瘤。
- 共分析400例腺瘤,其中208例(52%)有绒毛成分和/或高级别上皮内瘤变:186例(47%)有绒毛成分,41例(10%)有高级别上皮内瘤变。
- 仅1例腺瘤存在错配修复蛋白缺失,该腺瘤发现2个体细胞MSH6突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is important to identify individuals with Lynch syndrome because surveillance programs can reduce their morbidity and mortality from colorectal cancer (CRC). We assessed the diagnostic yield of immunohistochemistry to detect Lynch syndrome in patients with advanced and multiple adenomas within our national CRC screening program. METHODS: We performed a prospective study of all participants (n = 1101; 55% male; median age, 66 years; interquartile range, 61-70 years) referred to the Erasmus MC in The Netherlands after a positive result from a fecal immunohistochemical test, from December 2013 to December 2016. Colon tissues were collected from patients with advanced adenomas, ≥4 nonadvanced adenomas, or CRC, and analyzed by immunohistochemistry to identify patients with loss of mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, or PMS2): a marker of Lynch syndrome. Specimens from patients with loss of MLH1 were analyzed for MLH1 promoter hypermethylation. Patients with an MMR-deficient tumor or adenoma without MLH1 promoter hypermethylation were referred for genetic analysis. RESULTS: At colonoscopy, 456 patients (41%) (65% male; mean age, 67 years; interquartile range, 63-71 years) were found to have CRC and/or an adenoma eligible for analysis by immunohistochemistry. Of 56 CRCs, 7 (13%) had lost an MMR protein and 5 had hypermethylation of the MLH1 promoter. Analyses of tumor DNA revealed that 2 patients without MLH1 promoter hypermethylation had developed sporadic tumors. In total, 400 patients with adenomas were analyzed. Of the examined adenomas, 208 (52%) had a villous component and/or high-grade dysplasia: 186 (47%) had a villous component and 41 (10%) had high-grade dysplasia. Only 1 adenoma had lost an MMR protein. This adenoma was found to have 2 somatic mutations in MSH6. CONCLUSIONS: In a CRC screening program in The Netherlands for individuals aged 55 to 75 years, routine screening for Lynch syndrome by immunohistochemistry analysis of colon tissues from patients with advanced and multiple adenomas identified no individuals with this genetic disorder.
引用
- Goverde A, Wagner A, Bruno MJ, et al. Routine Molecular Analysis for Lynch Syndrome Among Adenomas or Colorectal Cancer Within a National Screening Program. Gastroenterology. 2018. PMID: 30063919. doi:10.1053/j.gastro.2018.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。